Abstract
A number of representative, recent advances achieved within the field of retrometabolic drug design are briefly summarized. For the soft drug approach, some of the results of recent in vivo studies of loteprednol etabonate, a soft corticosteroid approved by the FDA in 1998, are reviewed. For the chemical delivery system (CDS) approach, the latest advances achieved in the brain targeting of peptides such as kyotorphin and TRH analogues are described.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
